RCM
PCVX icon

RA Capital Management’s Vaxcyte PCVX Stock Holding History

RA Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$667M Buy
11,474,599
+750,000
+7% +$40.7M 7.07% 2
2025
Q4 		$495M Sell
10,724,599
-1,241,392
-10% -$55.5M 5.07% 5
2025
Q3 		$431M Hold
11,965,991
– – 5.31% 3
2025
Q2 		$389M Sell
11,965,991
-223,158
-2% -$7.32M 6.55% 2
2025
Q1 		$460M Buy
12,189,149
+3,499,959
+40% +$280M 7.69% 2
2024
Q4 		$711M Hold
8,689,190
– – 9.47% 2
2024
Q3 		$993M Buy
8,689,190
+485,436
+6% +$43.7M 11.45% 2
2024
Q2 		$619M Hold
8,203,754
– – 8.19% 2
2024
Q1 		$560M Buy
8,203,754
+312,500
+4% +$21.6M 7.13% 2
2023
Q4 		$496M Hold
7,891,254
– – 7.74% 3
2023
Q3 		$402M Hold
7,891,254
– – 7.92% 3
2023
Q2 		$394M Buy
7,891,254
+600,000
+8% +$28.4M 7.44% 3
2023
Q1 		$273M Buy
7,291,254
+1,433,795
+24% +$60.8M 6.19% 2
2022
Q4 		$281M Buy
5,857,459
+1,276,256
+28% +$50.1M 5.7% 2
2022
Q3 		$110M Hold
4,581,203
– – 2.35% 11
2022
Q2 		$99.7M Hold
4,581,203
– – 2.66% 8
2022
Q1 		$111M Buy
4,581,203
+340,739
+8% +$7.44M 2.41% 8
2021
Q4 		$101M Buy
4,240,464
+343,599
+9% +$7.99M 1.78% 14
2021
Q3 		$98.9M Buy
3,896,865
+31,057
+0.8% +$753K 1.37% 24
2021
Q2 		$87M Hold
3,865,808
– – 1.4% 21
2021
Q1 		$76.3M Buy
3,865,808
+155,109
+4% +$3.9M 1.15% 25
2020
Q4 		$98.6M Sell
3,710,699
-1,573,119
-30% -$58.5M 1.38% 24
2020
Q3 		$261M Sell
5,283,818
-205,363
-4% -$8.18M 4.77% 4
2020
Q2 		$174M Buy
+5,489,181
New +$177M 3.38% 6

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RA Capital Management's PCVX Position: Q1 2026 in Review

RA Capital Management increased its Vaxcyte (PCVX) stake by 7% in Q1 2026, buying an estimated $40.7M and bringing the position to 11,474,599 shares worth $667M. The position accounts for 7.07% of the portfolio, ranked #2.

RA Capital Management first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $993M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • RA Capital Management held 11,474,599 shares of Vaxcyte worth $667M as of Q1 2026.
  • RA Capital Management bought 750,000 Vaxcyte shares in Q1 2026, an estimated $40.7M.
  • Vaxcyte made up 7.07% of RA Capital Management's portfolio in Q1 2026, its #2 holding.
  • RA Capital Management first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • RA Capital Management's Vaxcyte position peaked at $993M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.